-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CTwdVLmSGCGv8CAhtp5Z7Q0644ZmYK5JlL7ZGyb/CVFBJcc0oNhA3zB797nYWya2 2sJICISa+o0hMVfh6IcjKQ== 0000950103-04-000122.txt : 20040129 0000950103-04-000122.hdr.sgml : 20040129 20040129133539 ACCESSION NUMBER: 0000950103-04-000122 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20040127 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20040129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 04551593 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 8-K 1 jan2904_8k.htm 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 27, 2004

Shire Pharmaceuticals Group plc
(Exact name of registrant as specified in its charter)

England and Wales
(State or other jurisdiction of incorporation)


0-29630 98-0359573
(Commission File Number) (I.R.S. Employer Identification No.)


Hampshire International Business Park,
Chineham, Basingstoke,
Hampshire RG24 8EP England
(Address of principal executive offices) (Zip code)

Registrant’s telephone number, including area code:  44 1256 894 000

    
(Former name or former address, if changed since last report)


Item 5. Other Events

     Shire Pharmaceuticals Group plc has issued the press releases attached as Exhibit 99.1 and Exhibit 99.2 and which are incorporated by reference herein.

Item 7. Financial Statements and Exhibits

     (c) Exhibits.    The following exhibits are filed herewith:

99.1       Press Release dated January 27, 2004
99.2       Press Release dated January 27, 2004

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

SHIRE PHARMACEUTICALS GROUP PLC

By:    /s/ A C Russell                  
       Name: Angus Russell
       Title:   Group Finance Director

 

Dated: January 27, 2004

EXHIBIT INDEX

Number      Description

99.1            Press Release dated January 27, 2004
99.2           Press Release dated January 27, 2004

EX-99.1 3 jan2904_ex991.htm

EXHIBIT 99.1

STOCK EXCHANGE ANNOUNCEMENT

27 January 2004

 

Shire Pharmaceuticals Group plc (the “Company”)

The Company announces that it was notified on 23 January 2004 under Sections 198 to 202 of the Companies Act that FMR Corp. and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries, both being non-beneficial holders, held solely for investment purposes in aggregate 60,216,907 ordinary shares of £0.05p each in the capital of the Company. These holdings represent 12.61 per cent of the issued ordinary share capital of the Company.

T May
Company Secretary

EX-99.2 4 jan2904_ex992.htm

EXHIBIT 99.2

STOCK EXCHANGE ANNOUNCEMENT

27 January 2004

 

Shire Pharmaceuticals Group plc (the “Company”)

The Company announces that it was notified on 26 January 2004 under Sections 198 to 202 of the Companies Act that on 23 January 2004 Franklin Resources, Inc. and its affiliates had holdings managed on behalf of investment clients of 68,155,799 ordinary shares of £0.05p each in the capital of the Company. These holdings represent 14.2545 per cent of the issued ordinary share capital of the Company.

T May
Company Secretary

-----END PRIVACY-ENHANCED MESSAGE-----